EP1148902A1 - Method of enhancing needleless transdermal powdered drug delivery - Google Patents

Method of enhancing needleless transdermal powdered drug delivery

Info

Publication number
EP1148902A1
EP1148902A1 EP00900726A EP00900726A EP1148902A1 EP 1148902 A1 EP1148902 A1 EP 1148902A1 EP 00900726 A EP00900726 A EP 00900726A EP 00900726 A EP00900726 A EP 00900726A EP 1148902 A1 EP1148902 A1 EP 1148902A1
Authority
EP
European Patent Office
Prior art keywords
skin
particles
mucosa
use according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00900726A
Other languages
German (de)
English (en)
French (fr)
Inventor
Sung-Yun Kwon
Terry Lee Burkoth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Research Ltd
Original Assignee
Powderject Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Research Ltd filed Critical Powderject Research Ltd
Publication of EP1148902A1 publication Critical patent/EP1148902A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • a transdermal system as described above may be prepared as follows. An adhesive is cast onto a release liner. Solvent is evaporated therefrom, and the adhesive is then laminated onto the drug reservoir, which is in turn transfer-laminated onto the backing film. Alternatively, the drag reservoir may first be laminated to the backing layer and subsequently laminated to the precast adhesive layer.
  • the anode and cathode electrodes are in direct mechanical and electrical with the top sides of the reservoirs. The bottom sides of the reservoirs contact the patient's skin through openings in the adhesive, by which means the device adheres to the patient's body.
  • Vegetable oil permeation enhancers as described in U.S. Patent No. 5,229,130 to Sharma, may also be used.
  • oils include, for example, safflower oil, cotton seed oil and corn oil.
  • Film-forming polymer compositions and their use for delivery of pharmaceutically active agents to the skin are described in U.S. Patent No. 5,807,957 to S acre et al.
  • a modified Franz cell (6.9 ml) was used to investigate transdermal flux.
  • the receiver medium in the Franz cell was phosphate buffered saline (PBS) adjusted to pH 9.0 with NaOH and to which was added 2.5% TWEEN® 80 to minimize insulin adsorption to the glass and to maintain infinite sink conditions.
  • PBS phosphate buffered saline
  • TWEEN® 80 2.5% TWEEN® 80 to minimize insulin adsorption to the glass and to maintain infinite sink conditions.
  • the temperature of the receiver medium was maintained at 32° C during the studies.
  • the top of the Franz cell was covered with a full thickness (about 300 mm) sample of human cadaver skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
EP00900726A 1999-01-22 2000-01-21 Method of enhancing needleless transdermal powdered drug delivery Withdrawn EP1148902A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23594499A 1999-01-22 1999-01-22
US11690799P 1999-01-22 1999-01-22
US235944 1999-01-22
US116907P 1999-01-22
PCT/GB2000/000156 WO2000043058A1 (en) 1999-01-22 2000-01-21 Method of enhancing needleless transdermal powdered drug delivery

Publications (1)

Publication Number Publication Date
EP1148902A1 true EP1148902A1 (en) 2001-10-31

Family

ID=26814746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00900726A Withdrawn EP1148902A1 (en) 1999-01-22 2000-01-21 Method of enhancing needleless transdermal powdered drug delivery

Country Status (6)

Country Link
EP (1) EP1148902A1 (enExample)
JP (1) JP2002535293A (enExample)
AU (1) AU765429B2 (enExample)
CA (1) CA2358584A1 (enExample)
IL (2) IL144380A0 (enExample)
WO (1) WO2000043058A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780397B2 (en) 1999-02-03 2005-03-17 Powderject Research Limited Hydrogel particle formulations
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
JP2006335754A (ja) * 2005-06-01 2006-12-14 Technofarm Axesz Kk 経皮投与剤担持薄膜とその製造法
FR2921562B1 (fr) * 2007-10-01 2012-06-15 Dbv Tech Dispositif adhesif pour application cutanee
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
CN103298507B (zh) * 2010-10-07 2015-08-26 麻省理工学院 采用线性洛仑兹力致动的无针射流注射系统递送固体和/或流体
US20130060209A1 (en) * 2011-05-12 2013-03-07 Parker Campbell Tyler Athletic Tape
EP2979714A1 (de) * 2014-08-02 2016-02-03 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend eine Membran
JP7834639B2 (ja) * 2019-11-01 2026-03-24 ダーレ エムビー インコーポレイテッド 二段階マイクロチップ薬物送達デバイスおよび方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5233169B1 (enExample) * 1971-04-14 1977-08-26
US4831023A (en) * 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
US5203768A (en) * 1991-07-24 1993-04-20 Alza Corporation Transdermal delivery device
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0952850A2 (en) * 1996-12-31 1999-11-03 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
IL120943A (en) * 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0043058A1 *

Also Published As

Publication number Publication date
AU3065000A (en) 2000-08-07
WO2000043058A1 (en) 2000-07-27
AU765429B2 (en) 2003-09-18
JP2002535293A (ja) 2002-10-22
IL144380A (en) 2007-07-24
CA2358584A1 (en) 2000-07-27
IL144380A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
US10391290B2 (en) Microneedle injection apparatus comprising a dual cover
Tiwary et al. Innovations in transdermal drug delivery: formulations and techniques
Gratieri et al. Next generation intra-and transdermal therapeutic systems: using non-and minimally-invasive technologies to increase drug delivery into and across the skin
Cross et al. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development?
EP3381500B1 (en) Microneedle injection apparatus comprising an inverted actuator
US20060036209A1 (en) System and method for transdermal delivery
KR20060127394A (ko) 경피 백신 전달 시스템 및 방법
US8920817B2 (en) Formulations for coated microprojections containing non-volatile counterions
JP2007510445A (ja) 経皮薬剤送達促進用の前処置法及びシステム
JP2004531578A (ja) ワクチンおよび遺伝子治療剤のマイクロカニューレによる皮内送達
EP1686904A2 (en) Ultrasound assisted transdermal vaccine delivery method and system
EP1335711A2 (en) Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
AU2001288774A1 (en) Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
AU765429B2 (en) Method of enhancing needleless transdermal powdered drug delivery
KR20170040767A (ko) 용해성 마이크로니들 마스크 키트
US20070196490A1 (en) Method of enhancing needleless transdermal powered drug delivery
KR102313520B1 (ko) 흡수 속도를 개선한 마이크로니들 시스템
Jain Transdermal drug delivery
Singhal et al. Transdermal Medical Devices: Formulation Aspects
HK40020591B (en) Iontophoretic microneedle device
MXPA06004476A (en) Pretreatment method and system for enhancing transdermal drug delivery
KR20170032809A (ko) Ｂ형 간염 치료를 위한 용해성 미세바늘 패치

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020523

17Q First examination report despatched

Effective date: 20020523

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080801